- Reviews (0)
- Quantity number indicates strip.
- 10 pcs tablet contain in each strip.
- Secrin® is indicated as an adjunct to diet and exercise to lower blood glucose in patients with noninsulin-dependant (type 2) diabetes mellitus (NIDDM).
DOSAGE AND ADMINISTRATION
There is no fixed dosage regimen for the management of diabetes mellitus with Secrin® or any other hypoglycemic agent. The initial and the maintenance dosage are set based on the results of regular check of glucose in blood and urine. Monitoring of glucose levels in blood and urine also serves to detect either primary or secondary failure of therapy. Usual starting dose: The usual starting dose of Secrin® as initial therapy is 1-2 mg once daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic agents should be started with 1 mg once daily, and should be titrated carefully. There is no exact dosage relationship between Secrin® and other oral blood glucose lowering agents. The maximum starting dose of Secrin® should be no more than 2 mg. Usual maintenance dose: The usual maintenance dose is 1 to 4 mg once daily. The maximum recommended dose is 8 mg once daily. After reaching of a dose of 2 mg, dosage increases should be made in increments of no more than 2 mg at 1-2 weeks intervals based upon the patient’s blood glucose response. Patients receiving other oral hypoglycemic agents: As with other sulfonylurea hypoglycemic agents, no transition period is necessary when transferring patients to Secrin®. Patients should be observed carefully (1-2 weeks) for hypoglycemia when being transferred from longer-half life sulfonylureas (e.g. chlorpropamide) to Secrin® due to potential overlapping of drug effect.
Glimepiride is contraindicated in patients with 1. Known hypersensitivity to the drug. 2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
Hypoglycemia, nausea, vomiting, diarrhea, abdominal pain, allergic skin reactions e.g. pruritus, erythema & urticaria and blurred vision may be reported.
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including NSAIDs and other drugs that are highly protein bound, such as salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, MAO inhibitors, beta adrenergic blocking agents, and clarithromycin. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include thiazides, and other diuretics, corticosteriods, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, and isoniazide. A potential interaction between oral miconazole and oral hypoglycemic drugs leading to severe hypoglycemia has been reported.
Only logged in customers who have purchased this product may leave a review.